FDA approves Octapharma’s latest therapy NUWIQ®, for people with hemophilia A. Clinical trial data showed good to excellent results overall.
January 22 is the deadline to submit research poster abstracts for the WFH 2016 World Congress in Orlando, Florida, July 24-28, 2016.
The goal of this activity is to discuss the unique challenges facing nurses who treat adults with hemophilia.
New Medscape Educational Activity for clinicians helps them identify common risks and devise optimal strategies for challenging scenarios.
FDA approves expanded use of Octapharma's WILATE for surgery in patients with VWD.
“Rare Coagulopathies” chapter provides an overview of rare factor deficiencies and platelet disorders.
Apply now for the Prix Henri Chaigneau award, the winner to be announced at WHF's 2016 World Congress in Orlando, FL, July 2016.
Latest Medscape activity discusses emerging data for managing hemophilia and helps clinicians evaluate how to use them in clinical practice.
NHF is partnering with McMaster University, an international leader on clinical practice guidelines, to develop evidence-based guidelines for hemophilia care.
Bristol-Myers Squibb’s Daklinza™ (daclatasvir) combined with Gilead 's Sovaldi®,and AbbVie Inc.’s Technivie™ had high success rates in clearing hepatitis C virus.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car